Alternatively, because PDAC stroma is supportive of tumor cell growth and a well-described modulator of therapy resistance, stable α-SMA levels in CAFs during drug treatment may itself be a marker of treatment resistance and requires additional validation in larger patient cohorts. The gene discussed is ACTA1; the disease is neoplasm.